NCT00669266

Brief Summary

The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
80mo left

Started Sep 2002

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress78%
Sep 2002Dec 2032

Study Start

First participant enrolled

September 1, 2002

Completed
5.7 years until next milestone

First Submitted

Initial submission to the registry

April 28, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 30, 2008

Completed
22.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2030

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2032

Last Updated

August 26, 2025

Status Verified

August 1, 2025

Enrollment Period

28.3 years

First QC Date

April 28, 2008

Last Update Submit

August 24, 2025

Conditions

Adrenal TumorsAdrenocortical CarcinomaCushing SyndromeConn SyndromePheochromocytoma

Study Arms (2)

Tumor

Tumor material and corresponding biosamples from patients with adrenal tumors

control group

Biomaterial from patients without adrenal tumor

Eligibility Criteria

AgeUp to 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with adrenal tumors

You may qualify if:

  • adrenal tumor detected by imaging

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Wuerzburg

Würzburg, 97080, Germany

RECRUITING

Related Publications (6)

  • Tamburello M, Altieri B, Sbiera I, Sigala S, Berruti A, Fassnacht M, Sbiera S. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine. 2022 Sep;77(3):411-418. doi: 10.1007/s12020-022-03074-z. Epub 2022 May 18.

    PMID: 35583844RESULT

  • Sbiera I, Kircher S, Altieri B, Lenz K, Hantel C, Fassnacht M, Sbiera S, Kroiss M. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Front Endocrinol (Lausanne). 2021 Dec 9;12:795116. doi: 10.3389/fendo.2021.795116. eCollection 2021.

    PMID: 34956100RESULT

  • Weigand I, Ronchi CL, Vanselow JT, Bathon K, Lenz K, Herterich S, Schlosser A, Kroiss M, Fassnacht M, Calebiro D, Sbiera S. PKA Calpha subunit mutation triggers caspase-dependent RIIbeta subunit degradation via Ser114 phosphorylation. Sci Adv. 2021 Feb 19;7(8):eabd4176. doi: 10.1126/sciadv.abd4176. Print 2021 Feb.

    PMID: 33608270RESULT

  • Weigand I, Schreiner J, Rohrig F, Sun N, Landwehr LS, Urlaub H, Kendl S, Kiseljak-Vassiliades K, Wierman ME, Angeli JPF, Walch A, Sbiera S, Fassnacht M, Kroiss M. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 2020 Mar 17;11(3):192. doi: 10.1038/s41419-020-2385-4.

    PMID: 32184394RESULT

  • Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assie G, Weigand I, Calebiro D, Schwarzmayr T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK, Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM, Fassnacht M, Beuschlein F; European Network for the Study of Adrenocortical Tumors (ENSAT). Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. J Clin Endocrinol Metab. 2016 Sep;101(9):3526-38. doi: 10.1210/jc.2016-1586. Epub 2016 Jul 7.

    PMID: 27389594RESULT

  • Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med. 2014 Mar 13;370(11):1019-28. doi: 10.1056/NEJMoa1310359. Epub 2014 Feb 26.

    PMID: 24571724RESULT

Biospecimen

Retention: SAMPLES WITH DNA

Germline DNA Tumor samples Serum Plasma Urine

MeSH Terms

Conditions

Adrenal Gland NeoplasmsAdrenocortical CarcinomaCushing SyndromeHyperaldosteronismPheochromocytoma

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsAdrenal Gland DiseasesEndocrine System DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeAdrenal Cortex NeoplasmsAdrenal Cortex DiseasesAdrenocortical HyperfunctionParagangliomaNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve Tissue

Study Officials

  • Martin Fassnacht, MD

    U of Wuerzburg

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Martin Fassnacht, MD

CONTACT

49-931-201-36507fassnacht_m@medizin.uni-wuerzburg.de

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Endocrinology

Study Record Dates

First Submitted

April 28, 2008

First Posted

April 30, 2008

Study Start

September 1, 2002

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2032

Last Updated

August 26, 2025

Record last verified: 2025-08

Locations

DE(1)